Inhibition of platelet-rich arterial thrombus in vivo: Acute antithrombotic effect of intravenous HMG-CoA reductase therapy

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 29, Issue 9, 2009, Pages 1271-1276

  Obi, Chike ^a   Wysokinski, Waldemar ^b,c   Karnicki, Krzystof ^b   Owen, Whyte G ^c   McBane, Robert D ^b,c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Division of Cardiology   (United States)

^c Mayo ClinicHiroshima University   (United States)

Author keywords

HMG CoA reductase inhibitors; Platelets; Pleiotropic effects; Statins; Thrombosis

Indexed keywords

MEVINOLIN; SIMVASTATIN; THROMBOCYTE IN 111; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAROTID ARTERY INJURY; CAROTID ARTERY THROMBOSIS; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; EXPERIMENTAL PIG; FEMALE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE FUNCTION; THROMBOGENESIS; TREATMENT OUTCOME; ANIMAL; BLOOD; CELL ORGANELLE; DISEASE MODEL; DOSE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; SWINE; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOSIS; TIME;

ANIMALS; BLOOD PLATELETS; CAROTID ARTERY INJURIES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFUSIONS, INTRAVENOUS; LOVASTATIN; ORGANELLES; PLATELET ACTIVATION; SWINE; THROMBOSIS; TIME FACTORS;

EID: 69849105377     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.109.190884     Document Type: Article

References (38)

1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
2. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711-1718.
3. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, Rouleau JL, Pedersen TR, Gardner LH, Mukherjee R, Ramsey KE, Palmisano J, Bilheimer DW, Pfeffer MA, Califf RM, Braunwald E; A to Z Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes (phase Z of the A to Z trial). JAMA. 2004;292:1307-1316.
4. Ray KK. Cannon CP. McCabe CH. Cairns R. Tonkin AM. Sacks FM. Jackson G. Braunwald E. PROVE IT-TIMI 22 Investigators. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2005;46:1405-1410.
5. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G, ARMYDA Investigators Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) study. Circulation. 2004;110:674-678.
6. Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G, Montinaro A, Di Sciascio G. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol. 2007;49:1272-1278.
7. Fonarow GC, Wright RS, Spencer FA; National Registry of Myocardial Infarction 4 Investigators. Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol. 2005;96:611-616.
8. Inoue I, Goto S, Mizotani K, Awata T, Mastunaga T, Kawai S, Nakajima T, Hokari S, Komoda T, Katayama S. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells. Life Sci. 2000;67:863-876.
9. Sukhova GK, Williams JK, Libby P. Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler Thromb Vasc Biol. 2002;22:1452-1458.
10. Shimada K, Miyauchi K, Daida H. Early intervention with atorvastatin modulates TH1/TH2 imbalance in patients with acute coronary syndrome: from bedside to bench. Circulation. 2004;109:e213-4.
11. Rezaie-Majd A, Maca T, Bucek RA, Valent P, Müller MR, Husslein P, Kashanipour A, Minar E, Baghestanian M. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterol-emic patients. Arterioscler Thromb Vasc Biol. 2002;22:1194-1199.
12. Omori H, Nagashima H, Tsurumi Y, Takagi A, Ishizuka N, Hagiwara N, Kawana M, Kasanuki H. Direct in vivo evidence of a vascular statin: a single dose of cerivastatin rapidly increases vascular endothelial responsiveness in healthy normocholesterolaemic subjects. Br J Clin Pharmacol. 2002;54:395-399.
13. Hernández-Perera O, Pérez-Sala D, Navarro-Antolín J, Sánchez-Pascuala R, Hernández G, Díaz C, Lamas S. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvasta-tin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest. 1998;101: 2711-2719.
14. Walter DH, Rittig K, Bahlmann FH, Kirchmair R, Silver M, Murayama T, Nishimura H, Losordo DW, Asahara T, Isner JM. Statin therapy accelerates re-endothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation. 2002;105:3017-3024.
15. Dupuis J, Tardif J-C, Cernacek P, Théroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: the RECIFE (Reduction of Cholesterol in Ischemia and Function of Endo-thelium) Trial. Circulation. 1999;99:3227-3333.
16. Bickel C, Rupprecht HJ, Blankenberg S, Espinola-Klein C, Rippin G, Hafner G, Lotz J, Prellwitz W, Meyer J; AtheroGene Group. Influence of HMGCoA reductase inhibitors on markers of coagulation, systemic inflammation and soluble cell adhesion. Int J Cardiol. 2002;82:25-31.
17. Porreca E, Di Febbo C, Amore C, Di Castelnuovo A, Baccante G, Donati MB, Cuccurullo F, Iacoviello L. Effect of lipid-lowering treatment on factor VII profile in hyperlipidemic patients. Thromb Haemost. 2000;84: 789-793.
18. Undas A, Brummel KE, Musial J, Mann KG, Szczeklik A. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation. 2001;103:2248-2253.
19. Undas A, Brummel-Ziedins KE, Potaczek DP, Stobierska-Dzierzek B, Bryniarski L, Szczeklik A, Mann KG. Atorvastatin and quinapril inhibit blood coagulation in patients with coronary artery disease following 28 days of therapy. J Thromb Haemost. 2006;11:2397-2404.
20. Masamura K, Oida K, Kanehara H, Suzuki J, Horie S, Ishii H, Miyamori I. Pitavastatin-induced thrombomodulin expression by endothelial cells acts via inhibition of small G proteins of the Rho family. Arterioscler Thromb Vasc Biol. 2003;23:512-517.
21. Bourcier T, Libby P. HMG CoA reductase inhibitors reduce plasmin-ogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol. 2000; 20:556-562.
22. McBane RD, Wysokinski WE, Chesebro JH, Owen WG. Antithrombotic action of endogenous porcine protein C activated with latent porcine thrombin preparation. Thromb Haemost. 1995;74:879-885.
23. Serebruany VL, Miller M, Pokov AN, Malinin AI, Lowry DR, DrPHc, Tanguay JF, Hennekens CH. Effect of statins on platelet PAR-1 thrombin receptor in patients with the metabolic syndrome (from the PAR-1 Inhibition by Statins [PARIS] Study). Am J Cardiol. 2006;97: 1332-1336.
24. Niederganga, F. Alcovera, A Knightb CG, Farndaleb RW, Barnesb WB, Francischettic IMB, Bonc C Leducc M. Convulxin binding to platelet receptor gpvi: competition with collagen related peptides*1. Biochem Biophys Res Comm. 2000;273:246-250.
25. Sanguigni V, Pignatelli P, Lenti L, Ferro D, Bellia A, Carnevale R, Tesauro M, Sorge R, Lauro R, Violi F. Short-term treatment with ator-vastatin reduces platelet cd40 ligand and thrombin generation in hyper-cholesterolemic patients. Circulation. 2005;111:412-419.
26. Piorkowski M, Fischer S, Stellbaum C, Jaster M, Martus P, Morguet AJ, Schultheiss H-P, Rauch U. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone is sufficient cholesterol-lowering enough to inhibit platelets? Am Coll Cardiol. 2007; 49:1035-1042.
27. Haramaki N, Ikeda H, Takenaka K, Katoh A, Sugano R, Yamagishi S, Matsuoka H, Imaizumi T. Fluvastatin alters platelet aggregability in patients with hypercholesterolemia possible improvement of intraplatelet redox imbalance via HMG-CoA reductase. Arterioscler Thromb Vasc Biol. 2007;27:1471-1477. 177.
28. Undas A, Brummel-Ziedins K, Mann KG. Statins and blood coagulation, Arterioscler Thromb Vasc Biol. 2005;25:287-294.
29. Colli S, Werba JP, Tremoli E. Statins in atherothrombosis. Semin Vasc Med. 2004;4:407-415.
30. Ferro D, Basili S, Alessandri C, Cara D, Violo F. Inhibition of tissue factor-mediated thrombin generation by simvastatin. Atherosclerosis. 2000;149:111-116.
31. Eto E, Kozai T, Cosentino F, Joch H, Luscher TF. Statins prevents TF expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathway. Circulation. 2002;105:1756-1759.
32. Bea F, Blessing E, Shelley MI, Shultz JM, Rosenfeld ME. Simvastatin inhibits expression of tissue factor in advanced atherosclerotic lesions of apolipoprotein E deficient mice independently of lipid lowering. Atherosclerosis. 2003;167:187-194.
33. Davidson MH, Lukacsko P, Sun JX, et al. A multiple-dose pharmaco-dynamic, safety, and pharmacokinetic comparison of extended-and immediate-release formulations of lovastatin. Clin Ther. 2002;24: 112-125.
34. Wysokinski WE, McBane RD, Owen WG. Individual propensity for arterial thrombosis. Atheroscler Thromb Vasc Biol. 1999;19:883-886.
35. Karnicki K, Owen WG, Miller RS, McBane RD II. Factors contributing to individual propensity for arterial thrombosis. Arterioscler Thromb Vasc Biol. 2002;22:1495-1499.
36. Wysokinski WE, Karnicki K, McBane RD II. Individual propensity for thrombosis: comparison of porcine venous and arterial circulations. Thromb Res. 2008;122:390-396.
37. Mueller HS. Forman SA. Menegus MA. Cohen LS. Knatterud GL. Braunwald E. Prognostic significance of nonfatal reinfarction during 3-year follow-up: results of the Thrombolysis in Myocardial Infarction (TIMI) phase II clinical trial. The TIMI Investigators. J Am Coll Cardiol. 1995;26:900-907.
38. National Health and Nutrition Examination Survey III (NHANES III), 1988-1994, CDC/NCHC, and the American Heart Association.